Another proteasome inhibitor, VR23, possess powerful anti- inflammatory activity reducing IL-6 in synovial cells from RA patients, and improving LPS-induced acute lung injury by decreasing neutrophil migration, TNF-α secretion, and tissue inflammation in a mice model (52). This evidence concerns the gene TNF and rheumatoid arthritis.